PuriCore plc

2009 Annual General Meeting Results

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 5 June 2009 - PuriCore (LSE: PURI), the life sciences company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, announces that Resolutions 1 to 10 were duly passed at its Annual General Meeting held earlier today. Proxy figures will be displayed shortly on the Company's investor website at http://investor.puricore.com.  

Copies of the resolutions have been filed with the United Kingdom Listing Authority's Document Viewing Facility and are available for inspection at:

The Financial Services Authority

UKLA Document Viewing Facility

25 The North Colonnade

Canary Wharf

London

E14 5HS

Enquiries:

About PuriCore

PuriCore plc (LSE: PURI) is a life sciences company focused on developing and commercializing proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitization. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C. difficile, E.coli, HIV, Human and Animal Influenza (including H5N1 Avian Influenza), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford, UK. 

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.